Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing

Doi, Yusuke; Lila, Amr S. Abu; Matsumoto, Haruna; Okada, Tomoko; Shimizu, Taro; Ishida, Tatsuhiro

doi:10.2147/ijn.s119069

Cited by 13 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In preclinical models and in patients with colorectal cancer, reductions in vascular density and/or increases in pericyte coverage have followed treatment with a range of strategies for VEGF inhibition 82–89 . More specifically, in preclinical models, changes in vascular density and maturity were correlated with a 1.25-fold to 3-fold increase in perfusion with the use of the VEGF antibody bevacizumab 87 , endostatin and paclitaxel eluting nanoparticles 85,86 , inhibitors of transforming growth factor-β (TGFβ) signalling 88 and metronomic dosing of 5-fluorouracil (5-FU) 90 ; correlations between increased perfusion, drug delivery and improved response to chemotherapy were reported 85–88 . In a clinical study, improvements in perfusion were observed in 7/30 patients with recurrent glioblastoma treated with cediranib, a tyrosine kinase inhibitor of VEGF signalling 91 .…”

Section: Methods To Enhance Drug Deliverymentioning

confidence: 99%

“…An advantage of exercise is that its effects on perfusion are chronic, whereas the temporal window of effectiveness for antiangiogenic agents may be limited and difficult to determine. Jain and others 86,90,92 have recently emphasized that metronomic dosing of angiogenesis inhibitors may lead to prolonged normalization. In any case, strategies that can prolong the vascular normalization window for angiogenesis inhibitors need to be identified and rigorously tested.…”

Section: Methods To Enhance Drug Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Transport of drugs from blood vessels to tumour tissue

2017

View full text Add to dashboard Cite

The effectiveness of anticancer drugs in treating a solid tumour is dependent on delivery of the drug to virtually all cancer cells in the tumour. The distribution of drug in tumour tissue depends on the plasma pharmacokinetics, the structure and function of the tumour vasculature and the transport properties of the drug as it moves through microvessel walls and in the extravascular tissue. The aim of this Review is to provide a broad, balanced perspective on the current understanding of drug transport to tumour cells and on the progress in developing methods to enhance drug delivery. First, the fundamental processes of solute transport in blood and tissue by convection and diffusion are reviewed, including the dependence of penetration distance from vessels into tissue on solute binding or uptake in tissue. The effects of the abnormal characteristics of tumour vasculature and extravascular tissue on these transport properties are then discussed. Finally, methods for overcoming limitations in drug transport and thereby achieving improved therapeutic results are surveyed.

show abstract

Section: Methods To Enhance Drug Deliverymentioning

confidence: 99%

Section: Methods To Enhance Drug Deliverymentioning

confidence: 99%

Transport of drugs from blood vessels to tumour tissue

2017

View full text Add to dashboard Cite

show abstract

“…The method for the preparation of Adr preloaded CC nanoparticles followed a previously described study, with minor modifications 11 . In brief, 300‐μL water containing Adr (2 mg) was dispersed in a well with water‐in‐oil reverse micro‐emulsion containing CaCl2 (100 mM).…”

Section: Methodsmentioning

confidence: 99%

“…Previous studies have shown that DDSs offers preferable protection to the loaded drugs upon in vivo circulation 9,10 . In addition, the DDSs can also increase the penetration and retention of drugs than its free forms 11 . Therefore, it has been confirmed by many parallel studies that DDS showed better anticancer performance compared to free drugs, which was widely recognized as a promising approach to elevate the performance of chemotherapy 12,13 .…”

Section: Introductionmentioning

confidence: 98%

Chondroitin sulfate modified and adriamycin preloaded hybrid nanoparticles for tumor‐targeted chemotherapy of lung cancer

Xiang

Liu

2020

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Promising cancer treatment requires the assistant of drug delivery systems (DDS) with the aim to increase the accumulation of drugs in tumor tissue. Herein, a hybrid DDS was successfully developed to integrate chondroitin sulfate (CS) and calcium carbonate (CC) in to one system. Anticancer drug adriamycin (Adr) was preloaded into CC nanoparticles to obtain Adr‐loaded CC nanoparticles (CC/Adr). The resulted CS‐CC/Adr nanoparticles as a biocompatible DDS was able to specifically target cancer cells to enhance the chemotherapy of lung cancer due to the surface modification of CS. Intracellular uptake as well as in vivo imaging results revealed the obtained CS‐CC/Adr nanoparticles (size of ~100 nm) showed CS mediated tumor specific accumulation into A549 and LLC cells than unmodified CC/Adr, in which the CD44 receptor might be involved, which finally resulted in stronger anticancer capability than Adr or CC/Adr. As a result, CS‐CC/Adr nanoparticles could be further extended to clinical administration in our future works.

show abstract

“…In mice bearing C26 murine colon tumors, Doi et al . administered sub-maximum-tolerated doses of S-1 for 7 days, prior to administering fluorescently labeled PEGylated liposomes [14]. Fluorescence in untreated tumors was often greater in the tumor periphery, whereas tumors treated with S-1 for 1 week showed greater overall liposome uptake, with more homogeneous distribution throughout the tumor.…”

Section: Cytotoxic Debulkingmentioning

confidence: 99%

Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery

Blocker

Shields

2017

Mol Imaging Biol

View full text Add to dashboard Cite

Molecular imaging is a vital tool to non-invasively measure nanoparticle delivery to solid tumors. Despite the myriad of nanoparticles studied for cancer, successful applications of nanoparticles in humans is limited by inconsistent and ineffective delivery. Successful nanoparticle delivery in preclinical models is often attributed to enhanced permeability and retention (EPR)-a set of conditions that is heterogeneous and transient in patients. Thus, researchers are evaluating therapeutic strategies to modify nanoparticle delivery, particularly treatments which have demonstrated effects on EPR conditions. Imaging nanoparticle distribution provides a means to measure the effects of therapeutic intervention on nanoparticle delivery to solid tumors. This review focuses on the utility of imaging to measure treatment-induced changes in nanoparticle delivery to tumors and provides preclinical examples studying a broad range of therapeutic interventions.

show abstract

Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing

Cited by 13 publications

References 37 publications

Transport of drugs from blood vessels to tumour tissue

Transport of drugs from blood vessels to tumour tissue

Chondroitin sulfate modified and adriamycin preloaded hybrid nanoparticles for tumor‐targeted chemotherapy of lung cancer

Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery

Contact Info

Product

Resources

About